The distribution and gender difference of CYP3A activity in Chinese subjects

被引:68
作者
Zhu, B [1 ]
Liu, ZQ [1 ]
Chen, GL [1 ]
Chen, XP [1 ]
Ou-Yang, DS [1 ]
Wang, LS [1 ]
Huang, SL [1 ]
Tan, ZR [1 ]
Zhou, HH [1 ]
机构
[1] Cent S Univ, Xiang Ya Sch Med, Pharmacogenet Res Inst, Changsha 410078, Hunan, Peoples R China
关键词
CYP3A; gender; menstrual cycle; midazolam;
D O I
10.1046/j.1365-2125.2003.01728.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To investigate the distribution of CYP3A activity in the Chinese population, and to test for gender-related differences in CYP3A activity. Methods Using midazolam as a probe drug, CYP3A activity in 202 Chinese healthy subjects (104 men) was measured by plasma 1'-hydroxymidazolam:midazolam (1'-OH-MDZ:MDZ) ratio at 1 h after oral administration of 7.5 mg midazolam. The different phases of the menstrual cycle including preovulatory, ovulatory and luteal phases of 66 women phenotyped with midazolam were recorded. The concentrations of 1'-OH-MDZ and MDZ in plasma were measured by HPLC Results A 13-fold variation of CYP3A activity (log1'-OH-MDZ:MDZ: range -0.949-0.203) was shown. The CYP3A activity was normally distributed as indicated by the frequency distribution histogram, the probit plot and the Kolmogorov-Smirnov test (P>0.05). The CYP3A activity of women was higher than that of men (median: -0.36 vs -0.43, P<0.05; 95% CI for difference: -0.127, -0.012). There was a significant difference in CYP3A activity between the three phases of the menstrual cycle. The activity was highest in the preovulatory phase and decreased sequentially in the ovulatory and luteal phases (P<0.05). Conclusions A normal distribution of CYP3A activity was observed in the Chinese population. The CYP3A activity is higher in female subjects than in males. CYP3A activity differed across the phases of the menstrual cycle.
引用
收藏
页码:264 / 269
页数:6
相关论文
共 27 条
[1]   PHARMACOKINETIC DRUG-INTERACTIONS WITH ORAL-CONTRACEPTIVES [J].
BACK, DJ ;
ORME, MLE .
CLINICAL PHARMACOKINETICS, 1990, 18 (06) :472-484
[2]   Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: Probe of CYP3A [J].
Carrillo, JA ;
Ramos, SI ;
Agundez, JAG ;
Martinez, C ;
Benitez, J .
THERAPEUTIC DRUG MONITORING, 1998, 20 (03) :319-324
[3]   INHIBITION OF ORAL-CONTRACEPTIVE STEROID METABOLIZING ENZYMES BY STEROIDS AND DRUGS [J].
GUENGERICH, FP .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (06) :2159-2163
[4]  
Haehner BD, 1996, MOL PHARMACOL, V50, P52
[5]   Effect of a 'vagomimetic' atropine dose on canine cardiac vagal tone and susceptibility to sudden cardiac death [J].
Halliwill, JR ;
Billman, GE ;
Eckberg, DL .
CLINICAL AUTONOMIC RESEARCH, 1998, 8 (03) :155-164
[6]   GENDER EFFECTS IN PHARMACOKINETICS AND PHARMACODYNAMICS [J].
HARRIS, RZ ;
BENET, LZ ;
SCHWARTZ, JB .
DRUGS, 1995, 50 (02) :222-239
[7]   EFFECT OF AGE AND GENDER ON THE ACTIVITY OF HUMAN HEPATIC-CYP3A [J].
HUNT, CM ;
WESTERKAM, WR ;
STAVE, GM .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (02) :275-283
[8]   SEQUENCE OF THE 5'-FLANKING REGION OF CYP3A5 - COMPARATIVE-ANALYSIS WITH CYP3A4 AND CYP3A7 [J].
JOUNAIDI, Y ;
GUZELIAN, PS ;
MAUREL, P ;
VILAREM, MJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 205 (03) :1741-1747
[9]   NO EVIDENCE OF A GENETIC-POLYMORPHISM IN THE OXIDATIVE-METABOLISM OF MIDAZOLAM [J].
KASSAI, A ;
TOTH, G ;
EICHELBAUM, M ;
KLOTZ, U .
CLINICAL PHARMACOKINETICS, 1988, 15 (05) :319-325
[10]   Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe [J].
Kharasch, ED ;
Russell, M ;
Garton, K ;
Lentz, G ;
Bowdle, TA ;
Cox, K .
ANESTHESIOLOGY, 1997, 87 (01) :26-35